JusticeItaly Official institution
Italy cancels marketing approval for diabetes drug Gliclazide Teva
Italy's medicines agency AIFA has formally cancelled the marketing authorization for the human medicine 'Gliclazide Teva' at the request of its holder. The decision was published in the Gazzetta Ufficiale, the official gazette, on 29 October 2026. The short notice does not give further details about the reasons.
What does it mean?
Gliclazide Teva is a medicine that can no longer be legally sold in Italy. The company that held the approval asked to give it up, so the authorization has been formally removed.
Who is affected?
Patients who use Gliclazide Teva and pharmacies or doctors who supply it in Italy.
What changes?
Before this notice, Gliclazide Teva was authorized for sale in Italy; it is now no longer authorized for marketing.